risperidone (Janssen Pharmaceutical)

Risperidone LAI (Long-Acting Injectable), marketed under the brand name Risperdal Consta, is an extended-release formulation of the atypical antipsychotic risperidone. Developed by Janssen Pharmaceuticals, it was the first second-generation antipsychotic to be available in a long-acting injectable format. The drug is encapsulated in polylactide-co-glycolide (PLGA) microspheres, which allow for a slow, sustained release of the active moiety over several weeks. Its primary mechanism of action involves potent antagonism of the dopamine D2 and serotonin 5-HT2A receptors, which helps manage both the positive and negative symptoms of schizophrenia. It is also indicated for the maintenance treatment of bipolar I disorder. Administered intramuscularly every two weeks, it is designed to improve treatment adherence and provide stable plasma concentrations compared to daily oral dosing.

Brand names

Risperdal Consta

Other names

risperidone LAIrisperidone long-acting injectionrisperidone microspheres